Senate Republicans on Tuesday displayed a shift in attitude toward pharmaceutical companies as they questioned seven top CEOs in a hearing about why their products have become so expensive, signaling they will work to pass new drug pricing laws.
Senate Republicans on Tuesday displayed a shift in attitude toward pharmaceutical companies as they questioned seven top CEOs in a hearing about why their products have become so expensive, signaling they will work to pass new drug pricing laws.